Clinical News
Surveys Play a Critical Role in Improving the Patient Experience
I used to dislike surveys, polls, and questionnaires. I understood why they existed — customer or patient feedback is important — but I never really saw anything change once I took a survey. I hadn’t considered that perhaps my feedback was unrealistic or didn’t...
Read More
Esbriet and Ofev Show Significant Benefits in Real-Life Clinical Setting
Treatment with Esbriet (pirfenidone) or Ofev (nintedanib) significantly slowed the progression of idiopathic pulmonary fibrosis (IPF) in a real-life clinical setting, an Italian study reported. The study, “Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis:...
Rare Disease Groups Welcome FDA’s Embrace of ‘Real World’ Data in Clinical Trials
In his 10 months on the job, Commissioner Scott Gottlieb of the U.S. Food and Drug Administration is earning praise for his efforts to make clinical trials for new therapies more flexible and responsive to the needs of rare disease patients. From cystic fibrosis to...
Let’s Talk About Marijuana
Mom and I had flown to Denver to meet a specialist and strategize treatment for my nontuberculosis mycobacterium. Part of the clinic visit concerned treating my barren appetite and nonstop nausea. We’d tried nearly every anti-nausea prescription by then, and nothing...
Why Are Clinical Trials So Important for Pulmonary Fibrosis?
Clinical trials are extremely important in advancing medicine, helping to better understand how diseases begin and their progression, and to ultimately find cures or ways to prevent the disease. Clinical trials for pulmonary fibrosis (PF) are no exception and are...
Medicine and Big Data: the Future of Clinical Trials and Discoveries in PH
In the age of big-data large computational power, scientists are hovering over a wealth of information that can unearth the next generation of medical discoveries and therapies. When patients visit a doctor, their information is often stored as an electronic medical...
Clinical Trial Shows TD139 as a Promising Therapy Against Pulmonary Fibrosis, Maker Says
Clinical trial results indicate that inhaled TD139 is an effective, safe and well-tolerated treatment for idiopathic pulmonary fibrosis (IPF), its maker, Galecto Biotech AB, has reported. The phase 1b/2a clinical trial (NCT02257177) was divided into two parts. Part 1...
IPF Patients with Chronic Cough Sought for Phase 2 Clinical Trial
Clinical trial results indicate that inhaled TD139 is an effective, safe and well-tolerated treatment for idiopathic pulmonary fibrosis (IPF), its maker, Galecto Biotech AB, has reported. The phase 1b/2a clinical trial (NCT02257177) was divided into two parts. Part 1...